TLDR Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
This study assessed the effectiveness of baricitinib, a JAK inhibitor, in treating 14 patients with severe alopecia areata. Over 3 to 12 months, 57% of patients experienced at least a 50% improvement in hair regrowth, with 21% achieving complete regrowth. Adverse events were mild. The study concludes that baricitinib is effective and well-tolerated for treating refractory alopecia areata, but larger trials are necessary to confirm these results.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
4 citations,
September 2022 in “Dermatologic Therapy” Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
40 citations,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
95 citations,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
